What it's for (Indications)
- Dapagliflozin is a widely utilized medication with multiple approved indications, reflecting its diverse therapeutic benefits.
- It is indicated for the improvement of glycemic control in adult patients diagnosed with type 2 diabetes mellitus (T2DM), serving as an adjunct to diet and exercise.
- Beyond its direct effects on blood glucose, dapagliflozin is also approved to significantly reduce the risk of cardiovascular death and hospitalization for heart failure in adults afflicted with heart failure, specifically those with reduced ejection fraction (HFrEF).
- This cardiovascular protection extends to adult patients with type 2 diabetes mellitus who have established cardiovascular disease or multiple cardiovascular risk factors, where it is indicated to reduce the risk of cardiovascular death.
- Furthermore, dapagliflozin plays a crucial role in nephroprotection, being indicated to reduce the risk of sustained estimated glomerular filtration rate (eGFR) decline, end-stage kidney disease, cardiovascular death, and hospitalization for heart failure in adults with chronic kidney disease (CKD) who are at risk of progression.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | The dosing regimen for dapagliflozin varies depending on the specific indication and patient renal function. For the management of type 2 diabetes mellitus, the typical starting dose is 5 mg orally once daily in the morning, which can be taken with or without food. If additional glycemic control is required and the 5 mg dose is well-tolerated, the dosage may be increased to 10 mg once daily. For adult patients with heart failure (HFrEF), the recommended dose is 10 mg orally once daily in the morning, irrespective of food intake. Similarly, for adults with chronic kidney disease, a dose of 10 mg orally once daily in the morning is prescribed, also independent of meals. Renal function is a critical consideration; for type 2 diabetes, initiation is not recommended in patients with an eGFR below 45 mL/min/1.73 m² due to diminished glycemic efficacy. For heart failure and chronic kidney disease indications, initiation can be considered in patients with an eGFR as low as 25 mL/min/1.73 m². However, continued use is not recommended if eGFR persistently falls below 15 mL/min/1.73 m², particularly for patients on dialysis where efficacy is negligible. |
Safety & Warnings
Common Side Effects
- Patients receiving dapagliflozin may experience a range of side effects, both common and potentially serious.
- Common adverse reactions frequently reported include genital mycotic infections, such as vulvovaginal candidiasis, balanitis, and vulvovaginal pruritus, along with urinary tract infections (UTIs) including cystitis.
- Other common effects encompass increased urination (polyuria), nasopharyngitis, nausea, constipation, influenza-like illness, and back pain.
- More serious and clinically significant adverse events, though less common, warrant immediate medical attention.
- These include diabetic ketoacidosis (DKA), which can surprisingly occur even with normal or near-normal blood glucose levels (euglycemic DKA), and necrotizing fasciitis of the perineum (Fournier's gangrene), a rare but severe infection.
- Patients are also at risk for acute kidney injury, urosepsis and pyelonephritis, symptomatic hypotension (especially in volume-depleted individuals), and hypoglycemia when dapagliflozin is co-administered with insulin or sulfonylureas.
- Severe hypersensitivity reactions, though infrequent, have also been reported.
Serious Warnings
- Black Box Warning: Dapagliflozin does not currently carry an FDA-mandated Black Box Warning. However, healthcare professionals and patients must be fully cognizant of several serious and potentially life-threatening adverse events associated with its use, which, while not a formal black box, represent critical safety information. Foremost among these is the risk of **diabetic ketoacidosis (DKA)**. This severe metabolic complication, characterized by high levels of ketones in the blood, can occur even with normal or only slightly elevated blood glucose levels (euglycemic DKA), making it challenging to diagnose. Conditions that can precipitate DKA, such as acute illness, reduced insulin dosage, surgery, or alcohol abuse, warrant particular vigilance. Another severe concern is **necrotizing fasciitis of the perineum (Fournier's gangrene)**, a rare but rapidly progressive and potentially fatal bacterial infection. Patients must be educated to seek immediate medical attention for any signs of pain, tenderness, redness, or swelling in the genital or perineal area accompanied by fever. The potential for **volume depletion leading to symptomatic hypotension** and **acute kidney injury** also necessitates careful monitoring, especially in elderly, renally impaired, or diuretic-treated patients.
- Several critical warnings are associated with dapagliflozin use, necessitating careful patient monitoring and education.
- **Diabetic Ketoacidosis (DKA):** Cases of DKA, some presenting atypically with euglycemia, have been reported in patients treated with SGLT2 inhibitors, including dapagliflozin.
- Risk factors include acute illness, surgery, pancreatic insufficiency, reduced insulin dose, and excessive alcohol intake.
- Clinicians should assess for DKA symptoms (e.
- g.
- , nausea, vomiting, abdominal pain, excessive thirst, shortness of breath) and consider temporary discontinuation in situations predisposing to ketosis.
- **Necrotizing Fasciitis of the Perineum (Fournier's Gangrene):** This rare but life-threatening bacterial infection of the perineum has been reported.
- Patients should be advised to seek immediate medical attention if they develop pain, tenderness, erythema, or swelling in the genital or perineal area, particularly if accompanied by fever or malaise.
- **Volume Depletion/Hypotension:** Due to its osmotic diuretic effect, dapagliflozin can lead to intravascular volume depletion, resulting in symptomatic hypotension, especially in elderly patients, those with renal impairment, or patients on loop diuretics.
- Careful monitoring of volume status and blood pressure is crucial.
- **Acute Kidney Injury:** Reports of acute kidney injury, sometimes severe enough to require hospitalization, have occurred.
- Assessment of renal function is recommended prior to initiation and periodically during treatment.
- **Urosepsis and Pyelonephritis:** The increased risk of urinary tract infections with SGLT2 inhibitors can progress to serious infections such as urosepsis or pyelonephritis, warranting prompt diagnosis and treatment of any suspected UTI.
How it Works (Mechanism of Action)
Dapagliflozin exerts its therapeutic effects by acting as a highly selective and reversible inhibitor of sodium-glucose co-transporter 2 (SGLT2). SGLT2 is a protein predominantly expressed in the S1 segment of the renal proximal tubules, where it is responsible for the vast majority (approximately 90%) of glucose reabsorption from the glomerular filtrate back into the systemic circulation. By inhibiting SGLT2, dapagliflozin effectively reduces the renal reabsorption of filtered glucose and consequently lowers the renal threshold for glucose (RTG). This inhibition leads to a substantial increase in the urinary excretion of glucose (glucosuria), thereby decreasing plasma glucose concentrations. This glucose-lowering effect is achieved independently of insulin secretion or insulin sensitivity. Beyond glycemic control, the sustained osmotic diuresis and natriuresis induced by SGLT2 inhibition contribute to a reduction in both preload and afterload on the heart, a decrease in intraglomerular pressure, and improved cardiac energetics, which collectively underpin its significant cardiovascular and renal protective benefits.